Sumit Goswami
Overview
Explore the profile of Sumit Goswami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar N, Pathak B, Kesarwani R, Goswami S, Khare A, Boruah B
Opt Lett
. 2023 May;
47(21):5509-5512.
PMID: 37219256
Here we introduce an in situ and non-intrusive surface and thickness profile monitoring scheme of thin-film growth during deposition. The scheme is implemented using a programmable grating array based zonal...
2.
Goswami S, Sharma A
Opt Lett
. 2021 Jul;
46(13):3279.
PMID: 34197435
This publisher's note contains corrections to Opt. Lett.46, 3065 (2021).OPLEDP0146-959210.1364/OL.431787.
3.
Goswami S, Sharma A
Opt Lett
. 2021 Jul;
46(13):3065-3068.
PMID: 34197380
The lossy mode resonance (LMR) phenomenon is almost exclusively limited to fiber optics, since the thin film configuration yields a relatively shallow resonance dip compared to its fiber counterpart. In...
4.
Sreedhara A, Zamiri C, Goswami S, Weiser S, Cram M, Christian T, et al.
J Pharm Sci
. 2019 Nov;
109(1):22-29.
PMID: 31697946
Hazardous drug is a common term used by the National Institute of Occupational Health and Safety (NIOSH) to classify medications that may induce adverse mutagenic and reproductive responses in health...
5.
Tomar D, Kumar S, Singh S, Goswami S, Li L
MAbs
. 2016 Jan;
8(2):216-28.
PMID: 26736022
Effective translation of breakthrough discoveries into innovative products in the clinic requires proactive mitigation or elimination of several drug development challenges. These challenges can vary depending upon the type of...
6.
Qureshi T, Goswami S, McClintock C, Ramsey M, Peterson C
Protein Sci
. 2015 Nov;
25(2):499-510.
PMID: 26548921
Unlabelled: Plasminogen activator inhibitor-1 (PAI-1) is a biologically important serine protease inhibitor (serpin) that, when overexpressed, is associated with a high risk for cardiovascular disease and cancer metastasis. Several of...
7.
Nichols P, Li L, Kumar S, Buck P, Singh S, Goswami S, et al.
MAbs
. 2015 Jan;
7(1):212-30.
PMID: 25559441
High viscosity of monoclonal antibody formulations at concentrations ≥100 mg/mL can impede their development as products suitable for subcutaneous delivery. The effects of hydrophobic and electrostatic intermolecular interactions on the...
8.
Behrens M, Botkjaer K, Goswami S, Oliveira C, Jensen J, Schar C, et al.
J Mol Biol
. 2011 Jun;
411(2):417-29.
PMID: 21669207
A key regulatory step for serine proteases of the trypsin clan is activation of the initially secreted zymogens, leading to an increase in activity by orders of magnitude. Zymogen activation...
9.
Thompson L, Goswami S, Peterson C
Protein Sci
. 2011 Feb;
20(2):366-78.
PMID: 21280128
Human plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor with a metastable active conformation. The lifespan of the active form of PAI-1 is modulated via interaction with...
10.
Thompson L, Goswami S, Ginsberg D, Day D, Verhamme I, Peterson C
Protein Sci
. 2011 Feb;
20(2):353-65.
PMID: 21280127
Human plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor with a metastable active conformation. Under physiological conditions, half of the inhibitor transitions to a latent state within...